文献速递乳腺癌

法国个性化报销模型数据库中逾2万例接受HER2靶向治疗的乳腺癌患者真实世界治疗策略演变(2011-2018)

Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).
PubMed 文献 · Eur J Cancer · 2020-11-08

基于法国120家随机抽取医院的电子药房记录系统,2018年9月提取26,350例乳腺癌患者数据,分析2011年以来21,119例接受注射用HER2靶向治疗(曲妥珠单抗、帕妥珠单抗或T-DM1)的HER2过表达乳腺癌患者的治疗策略演变。结果显示早期乳腺癌中89.2%接受曲妥珠单抗联合至少紫杉类,转移性乳腺癌中帕妥珠单抗2014年获批后一线联合使用占67.4%,曲妥珠单抗-紫杉类从47.2%降至9.2%,T-DM1二线使用占53.8%。

要点

  • 早期HER2+乳腺癌中89.2%接受曲妥珠单抗联合至少紫杉类治疗。
  • 转移性乳腺癌一线帕妥珠单抗联合使用占67.4%,曲妥珠单抗-紫杉类从47.2%降至9.2%。
  • T-DM1作为二线治疗使用占53.8%。

核心结论

  • 该大型法国项目提供了HER2+乳腺癌真实世界治疗策略演变的可靠信息,数据提示最佳药物利用仍有显著改善空间。

研究设计与样本

  • 利用法国120家随机抽取医院的电子药房记录系统,2018年9月提取26,350例乳腺癌患者数据,分析2011年以来21,119例接受注射用HER2靶向治疗的患者。

主要发现

  • 早期乳腺癌患者16,398例,其中89.2%接受曲妥珠单抗联合至少紫杉类,曲妥珠单抗-紫杉类-蒽环类占62.6%。
  • 转移性乳腺癌患者6,030例,一线治疗占80.3%,二线占40.1%,三线及以上占28.3%。
  • 帕妥珠单抗2014年获批后,一线联合使用占总病例67.4%,曲妥珠单抗-紫杉类从47.2%降至9.2%。
  • T-DM1作为二线治疗使用占53.8%。

临床怎么用

  • 真实世界数据可用于评估临床实践与指南推荐的依从性,并构建药物相关指标以支持未来基于价值的定价方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a growing need for real-world data on cancer treatments usage, especially to assess compliance with recommendations. We developed a French project using hospital data to analyse evolution in the therapeutic strategies implemented in patients with human epidermal growth factor receptor 2 (HER2)-overexpressed (HER2+) breast cancer (BC) and exposed to injectable HER2-targeted therapies, i.e. trastuzumab, pertuzumab or trastuzumab emtansine (T-DM1). PATIENTS AND METHODS: Data from 26,350 women with BC were extracted in September 2018 from the Electronic Pharmacy Record systems of 120 French randomly recruited hospitals. Evolution in the treatments used, and combination regimens were described from 2011, in accordance with the BC stage and treatment line. RESULTS: Overall, 21,119 patients treated since 2011 were analysed: 16,398 patients with early BC (eBC) and 6030 patients with metastatic BC (mBC) including patients treated at both stages. In eBC, 89.2% of patients received trastuzumab combined with at least taxanes (trastuzumab-taxane-anthracycline: 62.6%). Patients with mBC were treated in the first line (80.3%) and/or the second line (40.1%) and/or ≥ the third line (28.3%). After its approval in 2014, pertuzumab was first used in first-line therapy combinations in 67.4% of the total cases, while trastuzumab-taxane decreased from 47.2% to 9.2%. Similarly, T-DM1 was used as the second-line treatment in 53.8% of cases. CONCLUSIONS: Given recent changes in available treatments for patients with HER2+ BC, this large French project provides robust information on real-world evolution in therapeutic strategies. Our data suggest there is room for significant improvement in optimal drug utilisation. Such data will be useful to build drug-related indicators for future value-based pricing solutions.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Cottu P, Coudert B, Perol D, et al. Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018). Eur J Cancer. 2020. PMID: 33176232. doi:10.1016/j.ejca.2020.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。